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Abstract
Introduction: To report response rates, progression-free survival (PFS) 
and overall survival (OS) in patients with advanced pancreatic cancer 
treated with different available chemotherapeutic regimens over 10 years. 
Materials and Methods: This is a retrospective observational study. All 
patients with locally advanced and metastatic pancreatic cancer (MPC) at 
Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, 
Pakistan, from January 2008 to December 2017 were studied. Data 
were collected from the hospital information system. The characteristics 
and outcomes of all the patients were analysed. PFS and OS were also 
estimated. Kaplan–Meier curves and log-rank test were applied, and SPSS 
version  20 was used for data analysis. Results: Eighty-seven subjects 
with a median age of 56  years (range 21–76) were included. Sixty-two 
(71%) subjects were male. The most common tumour location was the 
head of the pancreas in 46  (53%) of all the subjects. Sixty-three (72%) 
subjects had elevated carbohydrate antigen-19.9 values. About 47 (54%) 
subjects had locally advanced pancreatic cancer (LAPC), and 40  (46%) 
subjects had MPC. Chemotherapy regimens used were FOLFIRINOX 
in 23  (26%), gemcitabine (GEM) based in 66  (65%) and capecitabine 
(CAP) based in 8 (9%) of the subjects. One (1%) subject had a complete 
response, 12  (14%) had a partial response, 10  (11%) had stable disease 
and 59  (68%) of the subjects had progressive disease. The objective 
response rate (ORR) was 15% and the disease control rate (DCR) was 
26%. In MPC, the ORR was 10%, DCR was 18% and tumour progression 
was seen in 72% of the patients, while in LAPC, the ORR was 19.1, DCR 
34% and tumour progression was documented in 64% of the patients, 
respectively. The FOLFIRINOX chemotherapy regimen had better ORR, 
DCR and lesser number of progressions as compared to GEM- and CAP-
based chemotherapy regimens. The median PFS of the whole group was 
32  weeks, and the median OS was 54  weeks. The PFS was significantly 
higher for LAPC (39 weeks) as compared to the MPC group (25 weeks) 
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Introduction
Pancreatic ductal adenocarcinoma is one of the 
most typical gastrointestinal tract malignancies 
associated with dismal prognosis and an increasing 
impact on cancer-related mortality and one of the 
top five causes of cancer death worldwide despite 
being only the 11th most common cancer overall.[1-3]
Pancreatic cancer is clinically classified into 
three stages: Resectable, locally advanced 
and metastatic disease. The treatment strategy 
differs by the clinical stage, and it is important to 
determine the clinical stage in each pancreatic 
cancer patient to select the most appropriate 
treatment method.[4]
It usually arises in elderly patients with a mean 
age at onset of 71 years for men and 75 years for 
women with roughly equal incidence for both sexes. 
The clinical course of pancreatic cancer usually 
is aggressive, with a high symptom burden and 
potential for a substantial deterioration in the quality 
of life. The red flag symptoms prompting diagnosis 
appear only once the disease has already progressed 
or metastasised; thus, only 10–20% of pancreatic 
cancers are resectable at the time of presentation.[5-7]
The majority of patients present with advanced 
pancreatic cancers (locally advanced pancreatic 
cancer [LAPC] or metastatic pancreatic cancer 
[MPC]) have a very poor prognosis. The median 
overall survival (OS) is estimated to be 3–8 months. 
Moreover, the 5-year survival is around 1–3%, and 
the median life expectancy is approximately one 
year with current treatments.[6,8]
A few years back, the only chemotherapy shown 
to provide a modest survival benefit had been 
gemcitabine (GEM), which improved median OS 
from 4.4 to 5.6 months compared to fluorouracil in 
a Phase III study.[9] Attempts at improving survival 
with the combination of GEM and a variety of 
cytotoxic and molecularly targeted agents have 
failed to provide substantial additional benefit 
apart from the addition of erlotinib to GEM which 
was the only combination to provide a modest 
additional survival benefit of 6% at 1 year, resulting 
in an FDA approval for this agent.[1,10-12]
In May 2011, Conroy et al. published the trial results 
on FOLFIRINOX as the first regimen to improve 
the median OS of patients with MPC beyond 
10  months. This landmark trial was based on 
results of the initial Phase-II trial by Conroy et al. in 
2005, which confirmed the efficacy of FOLFIRINOX 
with promising response rates and a good safety 
profile.[13-15]
This study analysed the response rates in patients 
with advanced pancreatic cancer treated with 
different available chemotherapeutic regimens 
over 10  years. Furthermore, progression-free 
survival (PFS) and OS were calculated.
Methods
This retrospective study was done in a tertiary-
level cancer hospital, Shaukat Khanum Memorial 
Cancer Hospital and Research Centre, Lahore, 
Pakistan. A  total of 104 patients were registered 
with a proven diagnosis of advanced pancreatic 
cancer (both LAPC and MPC) from January 
(P = 0.028). There was no statistically significant difference between the OS of these two groups (P = 
0.451). In addition, PFS was significantly higher with FOLFIRINOX chemotherapy as compared to the 
other chemotherapy regimens. Regarding OS, there was no statistically significant difference among all 
chemotherapy regimen groups (P = 0.267). Conclusion: Based on our results, FOLFIRINOX remained 
the most effective chemotherapy regimen despite the dose modifications and toxicities in all groups, 
indicating that modified FOLFIRINOX could be considered as a first-line regimen in Southeast Asian 
population.
Key words: 5-flurouracil, cancer, capecitabine, chemotherapy, gemcitabine, pancreatic cancer, 
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2008 to December 2017. Inclusion criteria 
were histopathological diagnosis of advanced 
pancreatic cancer, age above 18 years and receipt 
of chemotherapy. Patients lost to follow-up before 
treatment completion were excluded from the 
analysis because their survival intervals were not 
available. The study protocols were reviewed by 
the Institutional Review Board of Shaukat Khanum 
Memorial Cancer Hospital and Research Centre, 
Lahore, Pakistan, and exemption was taken for 
informed consent as no direct interaction with 
patients was involved (EX-17-02-17-15).
The cancer diagnosis was made according to 
standard guidelines.[16] Patient characteristics such 
as age, gender, Eastern Cooperative Oncology 
Group-Performance Status (ECOG-PS), pancreatic 
tumour location, the extent of disease, level of 
carbohydrate antigen (CA) – 19.9 and computed 
tomography scan results (before and after 
treatment) were analysed. Types of chemotherapy 
regimen were also recorded. The objective tumour 
responses included complete response (CR), partial 
response (PR), progressive disease (PD) and stable 
disease (SD). The objective response rate (ORR) was 
defined as the ratio between the number of patients 
achieving objective response (complete or PR) and 
the total number of patients in the study regardless 
of the number of patients that underwent disease 
response evaluation. Likewise, disease control 
rate (DCR) was defined as the ratio between the 
number of patients achieving disease control (CR, 
PR and SD) and the total number of patients in the 
study, regardless of the number of patients that 
underwent disease response evaluation. All of 
these evaluations were done using the standard 
RECIST criteria.[17]
PFS was defined as the duration from the start 
of treatment to disease progression or death, 
whichever occurred first. OS was defined as the 
time interval from enrolment of the patient in the 
hospital to death from any cause or to last clinical 
follow-up.
Distributions were determined as frequencies and 
percentages for categorical variables. For continuous 
variables, mean, median, standard deviation and 
range were computed. The primary efficacy variable 
was OS, and the secondary endpoints of the study 
were tumour response and PFS.
Log-rank test and Kaplan–Meier estimations were 
performed for both PFS and OS. Response rates 
were calculated. Chi-square and Fisher exact tests, 
when suitable, were used to compare qualitative 
data. The difference was assumed to be significant 
when P ≤ 0.05 and all tests were two sided. The 
analysis was conducted using SPSS version 20.
Results
A total of 104 patients were identified. However, 
17  patients were excluded from the analysis 
because they had left the treatment before 
completion.
Eighty-seven patients met the inclusion criteria 
and were included in the analysis. Among the 
87 subjects included in the analysis, 62  (71%) 
subjects were male, and 25  (29%) were female. 
The median age was 56 ± 12.03 years (range 21–
76 years). The ECOG-PS was 0, 1 and 2 in 24 (28%), 
50 (57%) and 13 (15%) subjects, respectively. The 
most common tumour location was the head of 
the pancreas in 46  (53%) subjects. Twenty-four 
(28%) subjects had normal CA – 19.9 values and 
it was elevated in 63 (72%) subjects. Forty-seven 
(54%) subjects had LAPC, and 40 (46%) subjects 
had MPC. Chemotherapy regimens used were 
FOLFIRINOX in 23 (26%), GEM based in 66 (65%) 
and capecitabine (CAP) based in 8  (9%) of the 
subjects [Table 1].
One (1%) subject had a CR, 12  (14%) had a PR, 
10 (11%) had SD and 59 (68%) of the subjects had 
PD. The ORR was 15%, and the DCR was 26%. In 
contrast, the response could not be evaluated 
in 5  (6%) of the subjects due to various reasons, 
including complications during treatment leading 
to referral to best supportive care or death. In 
MPC, the ORR was 10%, DCR was 18% and tumour 
progression was seen in 72% of the subjects, 
while in LAPC, the ORR was 19.1, DCR 34% and 
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tumour progression was documented in 64% of 
the subjects, respectively [Table 2].
The tumour responses according to chemotherapy 
regimens are shown in Table 2, which demonstrates 
that 5-fluorouracil (5-FU)-based (FOLFIRNOX) 
chemotherapy regimen had better ORR, DCR 
as compared to GEM-based and CAP-based 
chemotherapy regimens. Furthermore, fewer 
subjects progressed in the FOLFIRINOX regimen 
as compared to other regimens. However, due to 
the unequal distribution of sample size, further 
statistical analysis for significance, could not be 
possible [Table 2].
The median PFS of the whole group was 32 weeks, 
and the median OS was 54  weeks. The PFS 
was significantly higher for LAPC (39  weeks) as 
compared to the MPC group (25 weeks) (P = 0.028) 
[Figure  1a]. However, there was no statistically 
significant difference between OS of these two 
groups (66  weeks for LAPC vs. 49  weeks MPC, 
respectively, P = 0.451) [Figure 1b].
Three subjects had successful surgical resection 
(Whipple), and two subjects had R1 resection. 
Unfortunately, all of these three subjects passed 
away within a year.
In addition, PFS was significantly higher with 5-FU-
based chemotherapy regimen (FOLFIRINOX) 
as compared to the other two chemotherapy 
regimens (101 weeks vs. 31 weeks vs. 19 weeks 
for 5-FU-, GEM-  and CAP-based thermotherapy, 
respectively, with P = 0.001) [Figure 2a]. Regarding 
OS, there was no statistically significant difference 
among all chemotherapy regimen groups 
(65  weeks vs. 63  weeks vs. 14  weeks for 5-FU-, 
GEM-  and CAP-based chemotherapy regimens, 
respectively, P = 0.267) [Figure 2b].
Discussion
The treatment for MPC is chemotherapy only, 
whereas, in LAPC, chemotherapy and radiotherapy 
have been employed to improve response rates 
and make them resectable in <5% of cases.[13] The 
purpose of this study was to assess the outcome of 
locally advanced and metastatic pancreatic cancer 
in the local population. The results of this study are 
consistent with the investigations conducted in the 
West and the South Asian region.
In this study, 87 subjects were analysed, of which 
62  (71%) were male. This is not in line with the 
findings from other investigators.[18,19] This disparity 
in gender distribution could be secondary to the 
regional culture or that the incidence of pancreatic 
cancer is different in this part of the world. The 
median age of the cohort was 56 years, which is 
not in broad agreement with the results from other 
international studies as they show a trend toward 
more advanced age.[18,19] The exact reason for 
the earlier onset of disease in the present study 
Table 1: This table shows the baseline 
characteristics and chemotherapy regimens
Characteristics Category Number (%)
Age (years) 56±12.03 
(median)
Gender Male 62 (71)
Female 25 (29)












CA 19.9 (units/ml) Normal
Low <59×ULN 35 (40)
Elevated ≥59×ULN 28 (32)




FOLFIRINOX based 23 (26)
GEM based 56 (65)
CAP based 8 (9)
ECOG-PS: Eastern Cooperative Oncology Group-Performance 
status, ULN: Upper limit of normal, 5-FU: 5-fluorouracil, GEM: 
Gemcitabine, CAP: Capecitabine
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is beyond the scope of this paper. However, it 
could be possible that elderly subjects were not 
well represented as they were too frail to receive 
chemotherapy.
Most of the patient had ECOG-PS 1, and 47 (54%) 
had LAPC, and 40 (46%) had MPC. Interestingly, 
most of the subjects had GEM 66 (65%), while only 
23  (26%) subjects went on to have FOLFIRINOX. 
The reasons for this could be the patient’s choice, 
physician’s recommendation due to patient’s 
logistics and risk of toxicities that might have 
affected the chemotherapy choice. Furthermore, 
the need for the PICC line flush required every 
Table 2: This table summarises the tumour responses based on chemotherapy regimens









CR 0 (0) 1 (2) 0 (0)
PR 7 (31) 5 (9) 0 (0)
SD 4 (17) 6 (11) 0 (0)
PD 11 (48) 42 (75) 6 (75)
Could not be assessed 1 (4) 2 (3) 2 (25)
ORR Overall 7 (31) 6 (11) 0 (0)
Locally advanced 5 (72) 4 (67) 0 (0)
Metastatic 2 (28) 2 (33) 0 (0)
DCR Overall 11 (48) 12 (22) 0 (0)
Locally advanced 8 (73) 8 (67) 0 (0)
Metastatic 3 (27) 4 (33) 0 (0%)
Tumour pro-
gression
Overall 11 (48) 42 (75) 6 (75)
Locally advanced 7 (64) 21 (50) 2 (33
Metastatic 4 (36) 21 (50) 4 (66)
CR: Complete response, PR: Partial response, SD: Stable disease, PD: Progressive disease, 5-FU: 5-fluorouracil, GEM: Gemcitabine, 
CAP: Capecitabine, ORR: Overall response rate, DCR: Disease Control rate
Figure 1: (a) This Kaplan–Meier survival curve summarises the progression-free survival according to the extent 
 of disease. (b) This Kaplan–Meier survival curve depicts the overall survival according to the extent of disease  
(LAPC: Locally advanced pancreatic cancer, MPC: Metastatic pancreatic cancer)
ba
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week, and logistic issues might affect the choice of 
chemotherapy. None of the subjects in the present 
study had GEM and nanoparticle albumin-bound 
paclitaxel (Nab-Paclitaxel) as it was not available 
in the hospital. The choice of chemotherapy has 
a significant bearing on the outcome, especially 
in good performance status, which needs to be 
looked at in future studies.
The median PFS in this study was 32 weeks, and 
OS was 54 weeks. However, after breaking down 
into the subjects with LAPC, the median PFS was 
clinically significant, 39 weeks and OS of 66 weeks. 
Median-free survival in MPC was 25 weeks, and OS 
was 49 weeks, consistent with other studies.[19,20]
The tumour control rate was 48% (11 out of 23 
subjects) in the FOLFIRINOX group compared 
to the 22% (12 out of 56 subjects) in the GEM 
group during the same time. PFS was significantly 
higher in the LAPC group than MPC. There might 
be multiple reasons for this, including better 
performance status, less dose reduction, choice of 
treatment (more 5FU-based chemotherapy in LAPC 
than in MPC) and perhaps the biology of cancer 
itself. More subjects were treated with 5FU-based 
chemotherapy in LAPC n = 16, 70%; MPC n = 7, 
30%. These results were similar to those reported 
in previous Phase III trials of chemotherapy in 
advanced pancreatic cancer.[13]
Unfortunately, the OS in this study was not different 
between the two groups. This is intriguing and 
could be explained by the smaller size of the cohort 
and warrant further studies. The ORR is compatible 
with the published international literature with 
more responses in FOLFIRINOX than GEM or CAP 
alone.[20]
For LAPC, the resection rates vary in different 
studies. In a systemic review of nearly 13 trials using 
FOLFIRINOX as neoadjuvant chemotherapy, the 
resection rates were reported from 0 to 43%, and 
R0 resection was reported in 74%.[21] Most of the 
studies from the South Asia region have looked 
at the surgical outcome in LAPC, and the data are 
very sparse on the long-term survival outcome of 
the patient who received any chemotherapy.[22] In 
this study, only three subjects out of 47 (6%) were 
deemed resectable, and out of three, two had R1 
resection. These subjects unfortunately relapsed 
within 3  months, and all of them died within 
12 months. All of these subjects were treated with 
FOLFIRINOX. This is again interesting as it seems 
that the outcome of these subjects was not much 
different from the one who did not have surgery. 
This is difficult to say with certainty as the number of 
subjects was small to make any robust conclusion.
This study had few limitations. First, this was a 
retrospective analysis, therefore liable to have 
Figure 2: (a) This Kaplan–Meier survival curve shows the progression-free survival according to chemotherapy  
regimens. (b) This Kaplan–Meier survival curve summarises the overall survival according to chemotherapy 
regimens (5-FU: 5-fluorouracil, GEM: Gemcitabine, CAP: Capecitabine)
ba
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selection bias and incomplete data collection, but as 
the electronic patient record was used to document 
and retrieve data, therefore, this should not be a 
case. Due to the small sample size, the outcome 
of subjects with LAPC who had curative surgery 
after chemotherapy could not be inferred robustly 
and need further studies with more significant 
numbers. Another limitation was the small number 
of subjects, which makes the analysis less robust. 
This is because the metastatic pancreatic subjects 
presenting to the hospital were not accepted for 
treatment as per the hospital policy. Therefore, only 
subjects who had LAPC or metastatic cancer not 
evident on the initial investigations (ultrasound liver 
and chest radiograph) were accepted, who later 
showed evidence of metastases on the subsequent 
imaging or during follow-up.
FOLFIRINOX emerged as the most successful 
chemotherapy regimen, albeit with dose reductions 
and toxicities. The subjects with both LAPC and 
MPC fared better on it. Modified FOLFIRINOX could 
be easily used in the Southeast Asian population 
with a similar outcome as shown in Western 
populations.
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